Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Protective effects of bone marrow mesenchymal stem cell-derived exosomes loaded cerium dioxide nanoparticle against deoxynivalenol-induced liver damage

Meng Z., Tang M., Xu S., Zhou X., Zhang Z., Yang L.

Animal Study on Chronic Inflammation, published in J Nanobiotechnology (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
J Nanobiotechnology (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40098176
PMCID
PMC11912777
DOI
10.1186/s12951-025-03316-y
Citations
4

Abstract (original English)

Background Deoxynivalenol (DON), a mycotoxin produced by Fusarium species, posed significant threats to food safety and human health due to its widespread prevalence and detrimental effects. Upon exposure, the liver, which played a crucial role in detoxifying DON, experienced depleted antioxidant levels and heightened inflammatory responses. Bone marrow mesenchymal stem cell (BMSC)-derived exosomes (BMSC-exos) exhibited therapeutic potential by promoting cellular repair and delivering bioactive substances, such as cerium dioxide nanoparticles (CeO₂ NPs), which are recognized for their ability to mitigate oxidative stress and inflammation. Results We successfully loaded BMSC-exos with CeO 2 NPs (BMSC-exos @ CeO 2 ) using extrusion techniques, verified through electron microscopy and elemental mapping. The resulting BMSC-exos @ CeO 2 displayed low cytotoxicity, boosted antioxidant activity, and reduced inflammation in Hepa 1-6 cells with DON condition. In vivo study, BMSC-exos @ CeO 2 maintained stability for 72 h, it also can prevent antioxidant depletion and inhibit liver inflammation under the DON condition. After BMSC-exos @ CeO 2 treatment, multi-omics analyses further highlighted significant changes in metabolic and protein signaling pathways, notably in linoleic and arachidonic acid metabolism. Key pathways about AMPK and JAK1/STAT3 were involved in mitigating liver damage

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
LiverMesenchymal Stem CellsAnimalsHumansMiceCeriumTrichothecenesAntioxidantsOxidative StressMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research